Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

被引:263
|
作者
Fechtner, Robert D. [2 ]
Godfrey, David G. [3 ]
Budenz, Donald [4 ]
Stewart, Jeanette A. [1 ]
Stewart, William C. [1 ]
Jasek, Mark C. [5 ]
机构
[1] PRN Pharmaceut Res Network LLC, Dallas, TX 75240 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Ophthalmol, Newark, NJ 07103 USA
[3] Glaucoma Associates Texas, Dallas, TX USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Alcon Labs Inc, Ft Worth, TX 76101 USA
关键词
glaucoma; therapy; ocular surface disease; OSDI; prevalence; DRY EYE SYNDROME; OPHTHALMIC EMULSION; DISEASE; EFFICACY; MODERATE; SAFETY;
D O I
10.1097/ICO.0b013e3181c325b2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP) lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and SDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 +/- 15.4 vs 15.4 +/- 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 +/- 15.6 vs 15.3 +/- 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 +/- 13.1, which was significantly lower than those of patients on 2 (16.7 +/- 17.0; P = 0.007) or 3 medications (19.4 +/- 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [21] Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
    Kaidi Wang
    Li Xu
    Zhilan Yuan
    Ke Yao
    Junmei Zhao
    Liang Xu
    Aiwu Fang
    Mingzhi Zhang
    Lingling Wu
    Jian Ji
    Jiamin Hou
    Qing Liu
    Xinghuai Sun
    BMC Ophthalmology, 14
  • [22] Impact of glaucoma medications and ocular surface disease on the quality of life of glaucoma patients in the district of Sousse (Tunisia)
    Leila, K.
    Gatfaoui, F.
    Mahjoub, A.
    Yakoubi, S.
    Krifa, F.
    Ghorbel, M.
    Mahjoub, H.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2019, 42 (05): : 464 - 470
  • [23] Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
    Ono, Koichi
    Sakemi, Fumika
    Marumoto, Tatsuya
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (02) : 605 - 611
  • [24] High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
    Ruangvaravate, Ngamkae
    Prabhasawat, Pinnita
    Vachirasakchai, Virunya
    Tantimala, Ratchadaporn
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (05) : 387 - 394
  • [25] Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection
    El Chehab, Hussam
    Le Corre, Anne
    Agard, Emilie
    Ract-Madoux, Guillaume
    Coste, Olivier
    Dot, Corinne
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2013, 23 (03) : 277 - 283
  • [26] Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
    Saini, M.
    Dhiman, R.
    Dada, T.
    Tandon, R.
    Vanathi, M.
    EYE, 2015, 29 (06) : 808 - 814
  • [27] A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy
    Denise, Ph.
    Lafuma, A.
    Khoshnood, B.
    Mimaud, V.
    Berdeaux, G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (03) : 601 - 608
  • [28] The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure
    Atey, Tesfay Mehari
    Shibeshi, Workineh
    Giorgis, Abeba T.
    Asgedom, Solomon Weldegebreal
    JOURNAL OF OPHTHALMOLOGY, 2017, 2017
  • [29] Intraocular pressure-lowering effect of Cordyceps cicadae mycelia extract in a glaucoma rat model
    Horng, Chi-Ting
    Yang, Ya-Lan
    Chen, Chin-Chu
    Huang, Yu-Syuan
    Chen, Chun
    Chen, Fu-An
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (04): : 1007 - 1014
  • [30] Neuroprotective and Intraocular pressure-lowering effects of (-)Δ9-tetrahydrocannabinol in a rat model of glaucoma
    Crandall, James
    Matragoon, Suraporn
    Khalifa, Yousuf M.
    Borlongan, Caesar
    Tsai, Nai-Tse
    Caldwell, Ruth B.
    Liou, Gregory I.
    OPHTHALMIC RESEARCH, 2007, 39 (02) : 69 - 75